Visit our new SENTRY Public Dataset at sentry-mvp.jmilabs.com

What is SENTRY?
The SENTRY Antimicrobial Surveillance Program was established in 1997 and now is one of the longest running antimicrobial surveillance programs in the world. SENTRY monitors worldwide pathogens and the changes in resistance patterns over time through centralized testing and utilizing reference susceptibility methods. SENTRY focuses on recruiting medical centers and hospital sites to participate each calendar in submitting organisms through a prevalence-based approach across a number of different types of infections. The study design collects clinical isolates under the following objectives: bloodstream, skin and soft tissue, respiratory, urinary tract, pathogens from patients hospitalized with pneumonia, intra-abdominal and invasive fungal infections. This prevalence based-approach requirement is critically important to measure the resistance patterns that guide local therapy, alert the scientific community of potential growing threats, and to steer antimicrobial research and development.

How can hospitals participate?
We recruit sites based on geography. The majority of our sites are in the United States and Europe, but we have a significant presence in Latin America, parts of Asia, and the Western Pacific. Contact SENTRY@jmilabs.com to learn how to enroll your hospital.

How can your drug be incorporated in the program?
New compounds and other agents can be integrated into the SENTRY platform by establishing agreements and transferring compounds at the beginning of the calendar year. JMI Laboratories bears the costs of the entire program. Each client only contracts for their desired surveillance data, such as geography or specific types of infections or pathogens, resulting in lower costs due to a shared platform approach.

What if you have unique surveillance requirements?
Clients that would like a more tailored surveillance program, such as wanting a unique set of sites to be recruited or certain set of organisms within their approved label of indicated species, can still participate in SENTRY. We would employ a hybrid approach. JMI Laboratories will take your preferred study parameters and create a special objective for SENTRY, thus achieving a unique program for you within our established support network.

Learn More

SENTRY Surveillance Program celebrated 20 years

The SENTRY Antimicrobial Surveillance Program celebrated 20 years of monitoring antimicrobial resistance worldwide with a supplement to Open Forum Infectious Diseases, an Infectious Diseases Society of America journal. Also check out two more anniversary publications, “The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program” in Antimicrobial Agents and Chemotherapy and “Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997–2016)” in Journal of Antimicrobial Chemotherapy.